ArticleViewAbstractPharmacognosy Journal,2022,14,4,445-449.DOI:10.5530/pj.2022.14.119Published:August 2022Type:Case ReportThalassemia β Major in Confirmed Covid-19 Patient: A Case ReportYosua Butar Butar, and Puspa Wardhani Yosua Butar Butar1,*, Puspa Wardhani2 1F1Clinical Pathology Specialist Medicine Academic Program, Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo General Regional Hospital, Surabaya, INDONESIA. 2Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo General Regional Hospital, Surabaya, INDONESIA. Abstract:The incidence of Thalassemia with confirmed Covid 19 is very rare. The aim of this study is to know the prognosis and evaluate the management of therapy in thalassemia β Mayor patients with COVID-19. This case study describes the progression of Thalassemia β Mayor with COVID 19 starting from how to establish the diagnosis of Thalassemia β Mayor and COVID 19 until how to treat thalassemia β Mayor patients with COVID-19 This case study result describes that COVID 19 aggravates thalassemia β Mayor. Infection can adversely affect thalassemia. Giving Blood transfusions must be done due to anemia in Thalassemia, but it will have an impact on the accumulation of iron in the body which will increase the severity of the infection. The administration of iron-chelation drugs is beneficial for Covid but on the other hand, it is contraindicated in Thalassemia patients. Keywords:COVID-19, Infection, Preventable Death, ThalassemiaView:PDF (578.97 KB) PDF Images Graphical Abstract ‹ Indonesian Medicinal Plants with Anti-inflammatory Properties and Potency as Chronic Obstructive Pulmonary Disease (COPD) Herbal Medicine up Massive Pleural Effusion with Adenosine Deaminase (ADA) Test Positive and COVID-19 Confirmed: A Case Report ›